Effect of Peroxisome Proliferator—Activated Receptor-γ Agonist Rosiglitazone on the Induction of Endometriosis in an Experimental Rat Model

Fazli Demirturk, Demirturk F, Fazlı Demirtürk, Hakan Aytan, Aytan H, Caliskan AC, Ahmet Çalışkan, Ahmet C Caliskan, Pelin Aytan, Aytan P, Dogan R Koseoglu, Koseoglu DR, Doğan Köseoğlu
Journal of the Society for Gynecologic Investigation · 2005 · vol. 13(1) , pp. 58–62 · doi:10.1016/j.jsgi.2005.10.002 · PMID:16378914 · W2063649743
article OA: closed CC0 ⤵ 38 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

Rosiglitazone, a PPAR-γ agonist, was investigated for its effect on the induction of endometriosis in a rat model.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectiveTo assess the effect of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist rosiglitazone on the induction of endometriosis in a rat model.MethodsEndometriosis was surgically induced in 28 rats by transplanting an autologous fragment of endometrial tissue onto the inner surface of the abdominal wall. Group I was assigned as control and no medication was administered. Starting 3 days before the operation and continuing for 4 weeks, 0.2 mg/kg/d rosiglitazone was administered to the study group orally. Four weeks later rats were killed and ectopic uterine tissues were evaluated morphologically and histologically. Scoring systems were used to evaluate preservation of epithelia.ResultsFour rats in the study group and one rat in the control group died of complications related to surgery. There was a significant difference in post-treatment spherical volumes (64.00 mm3 [interquartile range (IQR): 354.42] vs 41.60 mm3 [IQR: 37.87], P = .018) and explant weights (77.97 mg [IQR: 431.27] vs 47.24 mg [IQR: 43.01], P = .005) between control and rosiglitazone-treated groups. The epithelia were found to be preserved significantly better in the control group when compared with the roziglitazone-treated group (2.00 [IQR:2.00] vs 0.00 [IQR:2.25], P = .014).ConclusionsRosiglitazone was found to affect the induction of endometriosis negatively in this experimental rat model and seemed to interfere with the growth and maintenance of the uterine explant.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Endometriosis Hypoglycemic Agents Thiazolidinediones Animals Disease Models, Animal Endometriosis Endometrium Endometrium Female Hypoglycemic Agents Inflammation PPAR gamma PPAR gamma Rats Rats, Wistar Rosiglitazone Thiazolidinediones

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (38)

Cited by (38)

Source provenance

europepmc
last seen: 2026-07-27T06:15:28.040536+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:15:23.967219+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK